Biologics and Biosimilars (Combined Module)

Biologics and Biosimilars (Combined Module)

A badge with ribbon in color black 1 Point | An analog clock in color black 2h | A black calendar with white triangle in center that has a black exclamation point in the middle 30 Jun 2021 

Overview

How do I apply for CME credits?

*** To process your CME accreditation, please CLICK HERE to provide your college information. ***

MIMS will collect participation data for passing on to corresponding colleges. Also please check that your MIMS.com account has your up-to-date professional details, as these details will be printed on your course completion certificate.

If you have any enquiries, please contact MIMS via enquiry.hk@mims.com or call +852 2559 5888

The information contained on this site is intended for Healthcare Professionals only

The materials in this virtual exhibition are approved for use only in Hong Kong. Prescribing information may vary depending on local approval in each country. Therefore, before prescribing any product, always refer to local materials such as the prescribing information and/ or the Summary of Product Characteristics (SmPC).


Module 1 - Introduction to Biologics and Biosimilars


About this course

Module 1 of Biosimilar Modules for Continued Professional Development comprises three short videos. In the first video, the talk given by presenter Gay Gauvin, Global Operations Director, Biosimilars, Amgen, will provide healthcare professionals with a basic understanding of biological drugs, what differentiates them from small-molecule drugs, as well as the fundamentals of biosimilars development and manufacturing. In the second video, Julien Taïeb of Université Paris Descartes, France and Dr Gunar Stemer of Vienna General Hospital, Austria will talk the viewers through the regulatory pathway for biosimilar approvals. The third video provides insights from João Gonçalves of Faculty of Pharmacy at University of Lisbon, Portugal, Dr Stemer, Simon Cheesman of University College London Hospitals, United Kingdom, Mr Taïeb, and Dirk Arnold of Asklepios Tumorzentrun Hamburg, Germany regarding use of biosimilars in clinical practice.

Topics covered

  • Introduction to biological drugs/biologics
  • Defining biosimilars
  • Biosimilars’ manufacturing
  • Biosimilarity
  • Steps to regulatory approval
  • Extrapolation principle
  • Regulatory differences between biologics and biosimilars
  • Complex structure of biological molecules
  • Biosimilars’ pharmacovigilance
  • Benefits of biosimilars

Learning outcomes

  • Understanding of differences between biologics, biosimilars and small-molecule drugs
  • Basic comprehension of the biologics’ and biosimilars’ manufacturing process
  • Learning about biosimilarity
  • Understanding the differences in regulatory pathways between biologics and biosimilars
  • Learning about biologics’ and biosimilars’ complex structure and clinical implications
  • Discovering biosimilars’ potential benefits

Module 2 - Biosimilarity, Extrapolation and Immunogenicity


About this course

Module 2 of Biosimilar Modules for Continued Professional Development comprises two videos. In the first video, Dr Richard Markus, Vice President of Biosimilar Global Development at Amgen, talks about scientific justification of indication extrapolation and the optimal trial design for demonstrating biosimilarity. The second talk given by João Gonçalves of Faculty of Pharmacy at University of Lisbon, Portugal, focuses on immunogenicity of biological agents and its clinical impact.

Topics covered

  • Basis for extrapolation
  • Concept of totality of evidence
  • Key clinical trial features for demonstrating biosimilarity
  • Sensitive endpoint and patient populations
  • Immunogenicity as a feature of all biologics
  • Impact on bioavailability
  • Anti-drug antibodies (ADAs)
  • Sensitivity and specificity of detection assays
  • Clinical impact of immunogenicity
  • Safety of switching to and from biosimilars

Learning outcomes

  • Understanding the role reference product knowledge and totality of evidence play in justifying extrapolation
  • Knowing which endpoints would identify meaningful differences between reference product and biosimilar
  • Learning about immunogenicity and different types of ADAs
  • Understanding the effect of aggregation and impurity on immunogenicity
  • Discovering the potential clinical impact of immunogenicity
  • Being introduced to the concept of transient ADA response
  • Finding out if there are any safety issues associated with switching to and from biosimilars

Module 3 - Selecting and Prescribing a Biosimilar


About this course

Module 3 of Biosimilar Modules for Continued Professional Development comprises three videos. Dr. Gunar Stemer of Vienna General Hospital, Austria, Professor Irene Krämer of Medical Center of the Johannes Gutenberg-University, Mainz, Germany, Dr. Niels Boone of Zuyderland Medisch Centrum, Maastricht, The Netherlands, Julien Taïeb of Université Paris Descartes, France, Dirk Arnold of Asklepios Tumorzentrun Hamburg, Germany, and Simon Cheesman of University College London Hospitals, United Kingdom discuss what pharmacists need to consider when prescribing a biosimilar, the importance of educating all stakeholders with regards to biosimilar agents and challenges of biosimilars’ pharmacovigilance.

Topics covered

  • What pharmacists should consider when prescribing a biosimilar
  • Reliability of supply
  • Drug-related selection criteria
  • Patient-related selection criteria
  • Inter-batch variability of biologics and biosimilars
  • Challenges in extrapolating efficacy and risks between populations
  • Post-marketing surveillance
  • List of criteria necessary for European Medicines Agency approval
  • Selection matrix tool
  • Challenges in biosimilar selection and use
  • Pharmacovigilance
  • Education of physicians, pharmacists, nurses and patients on biosimilars

Learning outcomes

  • Considerations when prescribing a biosimilar
  • Appreciating the role of hospital pharmacists when selecting a biosimilar
  • Acceptance of variability of biologics and biosimilars
  • Understanding the differences in originator and biosimilars assessment
  • Learning about a selection matrix tool for biosimilars
  • Appreciating the importance of pharmacovigilance
  • Understanding the importance of educating physicians, pharmacists, nurses, and patients on biosimilars

CME Accreditors#:

Hong Kong College of Physicians (PP-PP)
Hong Kong College of Paediatricians (Cat E active)
The Medical Council of Hong Kong (Self-study)

#Please contact respective authorities directly for CME accreditation if it is not listed above


1 CME point available

  • A minimum score of 8/10 (80%) in the multiple-choice quiz is required to obtain 1 CME point.
  • A certificate can be downloaded upon successful completion.

Sponsored by

Amgen_logo_logotype.png


Organised by

Logo_comminuty_oncologists.png